EYEN: Had some time to do a little digging on the people running the company. It was not difficult to be impressed and allay any reservations that the co. is just a shell. Read the following from Bloomberg's public website on the CEO, Dr. Tsontcho Ianchulev.
"Dr. Tsontcho Ianchulev also known as Sean, M.D., MPH, has been Chief Executive Officer, Chief Medical Officer and Director at Eyenovia, Inc since March 12, 2014 and served as its Managing Director. Dr. Ianchulev served as Chief Medical Officer, Head of technology and business development and Vice President of Medical Affairs & Business Development of Transcend Medical, Inc from 2009 to February 2016. Dr. Ianchulev is the President of the KeepYourSight.org foundation. He serves on the faculty of the University of California San Francisco as a Clinical Assistant Professor. He is a prolific inventor, innovator, physician-executive and public health expert with deep life- science and medical technology expertise covering the spectrum of biotech and med-tech. As an innovator and technology developer, he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impActing medical care for hundreds of thousands of patients every year. As the Founder of Eyenovia, Dr. Ianchulev is also spearHeading new technology for piezostatic high-precision micro-therapeutics and as the Founder of Iantech, Inc. he is the inventor of micro-interventional, energy-free, phaco-fragmentation for cataract surgery. He served as a Venture Partner at Tullis Health Investors Inc. which he joined in 2008. He served as an Advisor of Tullis Health Investors Inc. also served as a Member of Advisory Board of the firm. In this role, Dr. Ianchulev Headed clinical development and medical affairs activities and was instrumental to the launch and success of Lucentis. He led a team of medical Directors and Scientists and oversees the clinical development and medical affairs activities in the ophthalmology group. He was the Founder of the Peristat Group, Inc, and was instrumental in the development of one of the few virtual diagnostic devices to receive FDA clearance for population screening via telemedicine and developed the first diagnostic device for remote telemonitoring of visual function and disease management of patients with glaucoma and macular degeneration. Dr. Ianchulev has over 15 years of experience in public health, life-science and medical technology. He was a Therapeutic Area Head in the Specialty Bio-Therapeutics and Non-Oncology Development organization at Genentech. Dr. Ianchulev was the Group Medical Director for the ophthalmology division and the Lucentis franchise at Genentech. While at Genentech, he Headed the ophthalmology research group and directed the development and the FDA approval of Lucentis, the most successful specialty biologic in the field of ophthalmology with more than $4Bn of annual sales. He is also the inventor of the first ophthalmic intraoperative biometry device, ORA - intraoperative aberrometry for high precision, infrared laser-guided cataract surgery, which dramatically improved the outcomes of cataract surgery with more than half a million patients treated to date. He was the patent holder and technology Founder of Wavetec Inc., which was acquired by Alcon/Novartis. In the glaucoma field, Dr. Ianchulev leads all the research and development efforts of the first suprachoroidal micro-stent (CyPass). He has been at the forefront of the next generation MIGS (Micro- Incisional Glaucoma Surgery) innovation and oversaw one of the largest glaucoma surgical research programs. For his leadership in public health, innovation and medicine, he was an invited expert by Congress during the deliberations on medical innovation and FDA regulation. He is a holder of multiple issued and pending patents. Dr. Ianchulev has multiple high-impact publications in the field, which have been cited by more than 2,000 peer-reviewed publications. He is a Professor of Ophthalmology at the New York Eye and Ear Infirmary and sits on the Boards of Iantech Medical, Kurobe Pharmaceuticals and The American Society of Cataract and Refractive Surgery Foundation. He also sits on a number of corporate and advisory Boards. He completed his specialty training at the Doheny Eye Institute, University of Southern California. Dr. Ianchulev earned an M.D. degree from Harvard Medical School, Harvard University. He also holds an M.P.H. in Health Policy, Management and Finance from the Harvard School of Public Health, Harvard University. Dr. Ianchulev received his bachelor of science from the University of Rochester."
